Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company that discovers, develops and commercializes cancer therapies targeting exportin 1 (XPO1), a protein involved in transporting molecules between a cell’s nucleus and cytoplasm. Its lead product, XPOVIO (selinexor), is an oral XPO1… From the company’s description.
Over the twelve months to Jun 30, 2026, Karyopharm Therapeutics Inc. reported revenue of $146.62M, up 6.8% from a year earlier, and a net loss of $224.74M. Its operating margin was −56.2%, and operations used $65.35M in cash. In fiscal 2025, it reported revenue of $146.07M, up 0.6% from fiscal 2024, and a net loss of $196.04M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Karyopharm Therapeutics Inc. does
In the company’s own words
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company that discovers, develops and commercializes cancer therapies targeting exportin 1 (XPO1), a protein involved in transporting molecules between a cell’s nucleus and cytoplasm. Its lead product, XPOVIO (selinexor), is an oral XPO1 inhibitor approved in the United States for certain patients with multiple myeloma and diffuse large B-cell lymphoma; outside the United States, it is also marketed as NEXPOVIO through partners. Karyopharm sells XPOVIO in the United States to patients through healthcare providers and specialty pharmacies, supported by commercial and patient-support teams, while partners handle commercialization in other territories. The company is developing selinexor for additional cancer indications, including myelofibrosis and endometrial cancer, and has another XPO1 inhibitor, eltanexor, in development. In fiscal 2025, Karyopharm reported $146.1 million in total revenue, including $114.9 million in net product revenue and $31.2 million in license revenue.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- NEWTON, MA
- Fiscal year end
- December
- CIK
- 1503802
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Karyopharm Therapeutics Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Karyopharm Therapeutics Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Karyopharm Therapeutics Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Karyopharm Therapeutics Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Karyopharm Therapeutics Inc.'s last four quarterly filings that the numbers alone won't show?”